Prevalence, Incidence, and Risk Factors for Human Papillomavirus 16 Seropositivity in Australian Homosexual Men
Isobel Mary Poynten, Fengyi Jin, David J Templeton, Garrett P Prestage, Basil Donovan, Michael Pawlita, Christopher K Fairley, Suzanne Garland, Andrew E Grulich, Tim Waterboer
Sexually Transmitted Diseases | LIPPINCOTT WILLIAMS & WILKINS | Published : 2012
Awarded by National Institutes of Health, a component of the US Department of Health and Human Services (NIH/NIAID/DAIDS: HVDDT Award)
Awarded by National Health and Medical Research Council in Australia
Awarded by NHMRC
Awarded by National Health and Medical Research Council. The Kirby Institute (formerly NCHECR)
The Health in Men cohort study was funded by the National Institutes of Health, a component of the US Department of Health and Human Services (NIH/NIAID/DAIDS: HVDDT Award N01-AI-05395), the National Health and Medical Research Council in Australia (Project grant 400944), and the New South Wales Health Department (Sydney). The Positive Health Cohort study was funded by the New South Wales Health Department (Sydney). The Health in Men and Positive Health Cohort studies were also funded by the Australian Government Department of Health and Ageing. Funding for HPV serology testing was from NHMRC program grant 568971. I.M.P. (1016307), F.J. (571402), and D.J.T. (1013353) are supported by Post-doctoral Training Fellowships from the National Health and Medical Research Council. The Kirby Institute (formerly NCHECR) is affiliated with the Faculty of Medicine, University of New South Wales and is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. I.M.P., F.J., D.J.T., G.P., M.P., and T.W. have no conflicts of interest. B.D. has received research funding from CSL Biotherapies Ltd and has been on the speakers' bureau for Merck and Sanofi-PasteurMSD. C.K.F. has received honoraria and research funding from CSL Biotherapies. C.K.F. owns shares in CSL Biotherapies the manufacturer for Gardasil and has received honoraria from Merck. S.G. has received advisory board fees and grant support from CSL and GlaxoSmithKline and lecture fees from Merck, GSK, and Sanofi Pasteur. S.G. has received funding through her institution to conduct HPV vaccine studies for MSD and GSK and is a member of the Merck Global Advisory Board and the Merck Scientific Advisory Committee for HPV. A.E.G. has received consulting fees and conference sponsorship from Merck, the manufacturer of the Gardasil quadrivalent HPV vaccine, and research funding, consulting fees, and conference sponsorship from CSL Biotherapies, the Australian distributor of the Gardasil vaccine.